Impact of BCL2 and p53 on postmastectomy radiotherapy response in high-risk breast cancer. A subgroup analysis of DBCG82 b&c
- 1 January 2008
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 47 (4), 608-617
- https://doi.org/10.1080/02841860802050746
Abstract
To examine p53 and BCL2 expression in high-risk breast cancer patients randomized to postmastectomy radiotherapy (PMRT). The present analysis included 1 000 of 3 083 high-risk breast cancer patients randomly assigned to PMRT in the DBCG82 b&c studies. Tissue microarray sections were stained with immunohistochemistry for p53 and BCL2. Median potential follow-up was 17 years. Clinical endpoints were locoregional recurrence (LRR), distant metastases (DM), overall mortality, and overall survival (OS). Statistical analyses included Kappa statistics, chi(2) or exact tests, Kaplan-Meier probability plots, Log-rank test, and Cox univariate and multivariate regression analyses. p53 accumulation was not significantly associated with increased overall mortality, DM or LRR probability in univariate or multivariate Cox regression analyses. Kaplan-Meier probability plots showed reduced OS and improved DM and LRR probabilities after PMRT within subgroups of both p53 negative and p53 positive patients. Negative BCL2 expression was significantly associated with increased overall mortality, DM and LRR probability in multivariate Cox regression analyses. Kaplan-Meier probability plots showed a significantly improved overall survival after PMRT for the BCL2 positive subgroup, whereas practically no survival improvement was seen after PMRT for the BCL2 negative subgroup. In multivariate analysis of OS, however, no significant interaction was found between BCL2 and randomization status. Significant reductions in LRR probability after PMRT were recorded within both the BCL2 positive and BCL2 negative subgroups. p53 was not associated with survival after radiotherapy in high-risk breast cancer, but BCL2 might be.Keywords
This publication has 45 references indexed in Scilit:
- Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c.Acta Oncologica, 2008
- Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapyBMC Cancer, 2007
- Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancerBreast Cancer Research and Treatment, 2006
- Prognostic and Predictive Effects of Immunohistochemical Factors in High-Risk Primary Breast Cancer PatientsClinical Cancer Research, 2006
- High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analysesInternational Journal of Cancer, 2005
- Emerging Role of P53, Bcl‐2 and Telomerase Activity in Egyptian Breast Cancer PatientsIUBMB Life, 2004
- Intratumor heterogeneity of biomarker expression in breast carcinomasBiotechnic & Histochemistry, 2004
- Prognostic significance of p53, bcl-2, and Bax expression in early breast cancerJournal of the American College of Surgeons, 2004
- Apoptosis suppressing protein bcl‐2 is expressed in well‐differentiated breast carcinomas with favourable prognosisThe Journal of Pathology, 1995
- p53 Status and the Efficacy of Cancer Therapy in VivoScience, 1994